Search clinical trials for: NAV5001

Total 11 results

Navidea Biopharmaceuticals

Withdrawn

A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

Parkinson's Syndrome

United States
Navidea Biopharmaceuticals

Terminated

Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

Parkinson's Syndrome

United States
Nuvamid SA
Medpace, Inc.; Anapharm; LGD

Active, not recruiting

Study of the Safety, Tolerability, and Pharmacokinetics of NUV001 Administered Orally to Healthy Adult Participants

Healthy Volunteers

United States
LGD
ProRelix Services LLP

Recruiting

Safety and Efficacy of Orally Administered NUV001 Nutraceutical Supplement in Sickle Cell Disease Patients

Sickle Cell Disease

India
Coegin Pharma AB
Bispebjerg Hospital; Studies&Me

Active, not recruiting

Phase I/IIa Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment Period in Adult Subjects With AK (COAKS)

Actinic Keratoses

Denmark
Avotres Inc.

Active, not recruiting

Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes

Type 1 Diabetes Mellitus

United States
Promius Pharma, LLC

Terminated

Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails

Onychomycosis

United States, Dominican Republic
Promius Pharma, LLC

Terminated

Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails

Onychomycosis

United States
LGD
Assistance Publique Hopitaux De Marseille; CEN Biotech; Etablissement Français...

Recruiting

Effect of NUV001 Supplementation in Patients Suffering From Sickle Cell Disease (SCD)

Sickle Cell Disease

France
Nitto Denko Corporation

Completed

Evaluation of the Safety and Immunogenicity of a Sublingual Influenza Vaccine NSV0001 in Healthy Male Volunteers

Influenza

Japan
Sumagen

Completed

Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients

HIV Infections

United States

3

Subscribe